T H E M E D I S S U E : O V A R I A N C A N C E R N E W S Ovarian Cancer Genome Sequencing Unveils Findings
By Vicki Brower S cientists may now have a better picture of the genomic landscape of ovarian cancer than of any other malignancy. A 15-group team of the Cancer Genome Atlas (TCGA) Research Network sequenced all the protein-coding segments, or exomes, of nearly 500 ovarian tumors.
"Because of the high number of tumors studied, the research fi lls in a lot of details not attainable with fewer samples," said Paul Spellman, Ph.D., TCGA computational scientist and an associate professor in the department of molecular and medical genetics at Portland's Oregon Health and Science University. Results of the sequencing illuminate mutations driving its development, important signaling pathways, and potential weaknesses. These results, published in the June 30 issue of Nature , offer a wealth of new information that, in time, could help researchers develop more targeted treatments for women with ovarian cancer.
The study examined genes from the most common and most aggressive ovarian tumor type, serous adenocarcinoma. Researchers confi rmed that a mutated TP53 tumor suppressor gene is involved in ovarian cancer: 97% of tumors in the study carried this mutation. Researchers also identifi ed mutations in nine other important genes that occur at much lower but statistically signifi cant rates, including BRCA1 and BRCA2; tumor suppressors RB1 (the retinoblastoma gene) and NF1 (the neurofi bromin gene); and a new tumor suppressor gene not previously associated with ovarian cancer, CDK12, a cyclin-dependent kinase.
According to Gad Getz, Ph.D., director of Cancer Genomics Informatics and Computational Biology at the Broad Institute, in Cambridge, Mass., "another important discovery is that, besides these mutations, ovarian cancer is largely driven by copy number changes [of genes] which are amplifi ed or deleted," he said, adding, "We have drugs for a number of these changes." For example, the mutations appear to be sensitive to the PARP [poly (ADP -ribose) polymerase] inhibitors used to treat women with BRCA1-and BRCA2-related breast cancer. Researchers also found a few patients with mutations in the BRAF gene, for which new drugs are being tested in other cancers.
TCGA is a large cooperative project funded by the National Cancer Institute and the National Human Genome Research Institute. TCGA started in 2006 to sequence 20 different tumor types, beginning with glioma. For ovarian cancer, the project has already spun off several important complementary studies. Collectively, these fi ndings could help elucidate a disease that, according to the American Cancer Society, occurs in an estimated 21,990 women per year and kills 15,460 annually, making it the deadliest cancer among women. "Drug research for ovarian cancer has lagged far behind other cancers because of the relatively low numbers of patients, in spite of the fact that it kills more proportionately than many other malignancies," said Douglas Levine, M.D., associate attending surgeon and head of the gynecological research lab at the Memorial Sloan -Kettering Cancer Center, in New York.
Ovarian Cancer Hallmarks
The Nature study confi rms previous research by David Bowtell, Ph.D., professor of cancer genomics and genetics at the Peter MacCallum Cancer Centre, in Melbourne, Australia. He found that the TP53 tumor suppressor gene is nearly always mutated in high-grade serous ovarian cancer and that TP53 damage occurs early in the genesis of ovarian cancer, rather than later as in colorectal cancer ( see 
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that TP53 mutation is both an early and ubiquitous event, what triggers it and whether it is the key molecular event from which the tumor evolves are critical questions," said Bowtell. If a TP53 mutation could be detected before clinical signs of the disease -when it is already advanced and incurable -treating patients early and arresting further development of ovarian cancer might be possible, he added. Currently, however, no test or drug treatment for this mutation exists.
The TCGA fi ndings also confi rmed that disruptions in the BRCA1/2 pathways are another hallmark of ovarian cancer. Defects in the BRCA pathway occur in approximately half of women with highgrade serous tumors. The alterations in the BRCA1 and BRCA2 DNA-repair genes may occur not only as germline mutations but also as independent somatic and epigenetic changes, said Spellman. "This suggests that these tumors may only require one defect to become a malignant phenotype," he said.
Levine agreed. "That P53 damage is an early event, taken together with three possible types of changes in BRCA1 and BRCA2, may be suffi cient to establish a tumor.
"In addition to the ubiquitous mutation of the TP53, it is very signifi cant that most other genetic changes were not high-frequency mutations but rather widespread copy number changes such as amplifi cations and deletions," Levine continued. Mutations are changes in the DNA sequence of a tumor, and copy number alterations mean that there are too many (amplifi cations) or too few (deletions) copies of the DNA, but the sequence is intact and not mutated. In many solid tumors, a driver mutation has been identifi ed in key genes and is present in 5% -25% of case patients. But in ovarian cancer, besides TP53, BRCA1, and BRCA2, few high-frequency mutations occur, but many copy number alterations do -more so than in most other solid tumors, Levine explained. "Copy number, in addition to TP53 mutations, is a major driver of ovarian cancer, unlike other solid tumors. This means that we must fi gure out how targeted therapies will work in copynumber -altered tumors in contrast to tumors with activating somatic mutations," he said.
Identifying Dysregulated Genes
Using TCGA data to seek sources of dysregulation other than tumor suppressors, Chad
Creighton, Ph.D., assistant professor of medicine at the Baylor College of Medicine, in Houston, searched for microRNAs (miRNAs) that might play an anticancer role. These miRNAs are small, noncoding, naturally occurring sections of RNA that govern various aspects of the cell cycle and stem cell differentiation, which are now being studied for their use as drugs to fi ght cancer. Creighton performed molecular profi les on normal and cancerous tissue samples and identifi ed one miRNA, mir31, which is associated with defects in the p53 pathway in ovarian cancer when its function is lost ( see March 2010 Cancer Research ) .
"This suggests that patients with cancers defi cient in the p53 pathway might benefi t from therapeutic delivery of this miRNA," Creighton said. "Our goal is to use miRNAs as drugs, employing nanoparticles for delivery into patients," he said. Creighton recently submitted to a journal new data that follow up the TCGA study. In that report, his team digs more deeply into the 2010 miRNA study, which combines gene expression and microRNA expression data to identify additional anticancer miRNAs and their associated gene targets.
The TCGA data also revealed defects in the RB1 and PI3K -RAS signaling pathways in 67% and 45% of tumors, respectively. These pathways govern cell growth, proliferation, differentiation, motility, and survival. Drugs for the PI3K pathway already exist and are being tested in ovarian and other cancers. Another commonly dysregulated pathway found was NOTCH, for which drugs are also in development. The study also identifi ed 168 epigenetically dysregulated genes, which indicates the potential use of demethylating drugs in ovarian tumors, Levine said.
Disease Sub-types
The TCGA study also supports earlier work by Bowtell indicating that high-grade serous ovarian cancer can be divided into four distinct molecular subtypes according to expression patterns ( see August 2008 Clinical Cancer Research ) . The new study identifi es similar subtypes, called immunoreactive, proliferative, differentiated, and mesenchymal, on the basis of gene clusters and predominant cell types that occur in tumors. "These tumor subtypes have more in common with other types of cancers, such as breast, endometrial, or renal clear cell cancer, than with each other," said Bowtell.
Bowtell has proposed a model of development of high-grade serous cancers, which the TCGA results support. An initial mutation of TP53 and BRCA or other DNArepair function occurs, followed by genomic instability and possibly enhanced by overexpression of certain proteins such as cyclin E1. This instability causes widespread copy number changes that in turn drives the tumor's evolution into one of four subtypes ( see November 2010 Nature Reviews Cancer ).
Cancer's Achilles Heel
A study in the July 1, 2011, preprint of the Proceedings of the National Academy of Sciences complements the TCGA results. It uses TCGA sequencing information to functionally test what the mutations and alterations it identifi ed actually do: Do they drive the growth of cancer, or are they merely "passengers" and unnecessary for its development? "Many genetic changes, whether mutations or alterations, occur when a tumor is developing as the genome is unstable," said principal investigator Bill Hahn, M.D., Ph.D., associate professor of medicine at Boston's Dana -Farber Cancer Institute. Hahn and colleagues established Project Achilles to fi nd cancer's weak spots. 
